Silencing of MBD1 reverses pancreatic cancer therapy resistance through inhibition of DNA damage repair

International Journal of Oncology

Volumn 42, Issue 6, 2013, Pages 2046-2052

  Xu, Jin ^a,b   Zhu, Wenwei ^a,b   Xu, Wenyan ^a,b   Cui, Xiaobo ^c   Chen, Leon ^c   Ji, Shunrong ^a,b   Qin, Yi ^a,b   Yao, Wantong ^a,b   Liu, Liang ^a,b   Liu, Chen ^a,b   Long, Jiang ^a,b   Li, Min ^a,b,c   Yu, Xianjun ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Chemoradiotherapy resistance; DNA damage repair; Methyl CpG binding domain protein 1; Pancreatic cancer

Indexed keywords

CISPLATIN; MBD1 PROTEIN; METHYL CPG BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL ACTIVATION; CHROMATIN; CONTROLLED STUDY; DNA DAMAGE; DNA DAMAGE CHECKPOINT; DNA REPAIR; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; RADIATION; SENSITIVITY ANALYSIS;

CELL CYCLE PROTEINS; CELL LINE, TUMOR; CHEMORADIOTHERAPY; CHROMATIN; CISPLATIN; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; RADIATION TOLERANCE; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 84876556334     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1901     Document Type: Article

References (33)

1. Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236, 2011.
2. Erkan M, Hausmann S, Michalski CW, et al: The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol 9: 454-467, 2012.
3. Wong HH and Lemoine NR: Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol 6: 412-422, 2009.
4. Olive K P, Jacobetz MA, Davidson CJ, et al: Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324: 1457-1461, 2009.
5. Garrido-Laguna I, Uson M, Rajeshkumar NV, et al: Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res 17: 5793-5800, 2011.
6. Terry SY and Vallis KA: Relationship between chromatin structure and sensitivity to molecularly targeted auger electron radiation therapy. Int J Radiat Oncol Biol Phys 83: 1298-1305, 2012.
7. Ng HH, Jeppesen P and Bird A: Active repression of methylated genes by the chromosomal protein MBD1. Mol Cell Biol 20: 1394-1406, 2000. (Pubitemid 30069259)
8. Lopez-Serra L, Ballestar E, Fraga MF, Alaminos M, Setien F and Esteller M: A profile of methyl-CpG binding domain protein occupancy of hypermethylated promoter CpG islands of tumor suppressor genes in human cancer. Cancer Res 66: 8342-8346, 2006. (Pubitemid 44449141)
9. Liu C, Chen Y, Yu X, et al: Proteomic analysis of differential proteins in pancreatic carcinomas: effects of MBD1 knockdown by stable RNA interference. BMC Cancer 8: 121, 2008.
10. Watanabe S, Ichimura T, Fujita N, et al: Methylated DNA-binding domain 1 and methylpurine-DNA glycosylase link transcriptional repression and DNA repair in chromatin. Proc Natl Acad Sci USA 100: 12859-12864, 2003. (Pubitemid 37339990)
11. Zhang Y, Chen LH, Wang L, Wang HM, Zhang YW and Shi YS: Radiation-inducible PTEN expression radiosensitises hepatocellular carcinoma cells. Int J Radiat Biol 86: 964-974, 2010.
12. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K and Linn S: Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 73: 39-85, 2004. (Pubitemid 39050363)
13. Bekker-Jensen S, Lukas C, Kitagawa R, et al: Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks. J Cell Biol 173: 195-206, 2006.
14. Jirawatnotai S, Hu Y, Michowski W, et al: A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature 474: 230-234, 2011.
15. Löbrich M, Shibata A, Beucher A, et al: gammaH2AX foci analysis for monitoring DNA double-strand break repair: strengths, limitations and optimization. Cell Cycle 9: 662-669, 2010.
16. Bartkova J, Horejsí Z, Koed K, et al: DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434: 864-870, 2005. (Pubitemid 40558993)
17. Kastan MB and Bartek J: Cell-cycle checkpoints and cancer. Nature 432: 316-323, 2004. (Pubitemid 39551659)
18. Chapman JR and Jackson SP: Phospho-dependent interactions between NBS1 and MDC1 mediate chromatin retention of the MRN complex at sites of DNA damage. EMBO Rep 9: 795-801, 2008.
19. Harper JW and Elledge SJ: The DNA damage response: ten years after. Mol Cell 28: 739-745, 2007. (Pubitemid 350217064)
20. Zhou BB and Elledge SJ: The DNA damage response: putting checkpoints in perspective. Nature 408: 433-439, 2000.
21. Yao W, Yu X, Fang Z, et al: Proflin1 facilitates staurosporine-triggered apoptosis by stabilizing the integrin beta1-actin complex in breast cancer cells. J Cell Mol Med 16: 824-835, 2012.
22. Shibamoto Y, Kubota T, Kishii K and Tsujitani M: Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, dorani-dazole. Radiother Oncol 56: 265-270, 2000. (Pubitemid 30601686)
23. Kim MP and Gallick GE: Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res 14: 1284-1285, 2008. (Pubitemid 351413904)
24. Parsels LA, Morgan MA, Tanska DM, et al: Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther 8: 45-54, 2009.
25. Krempler A, Deckbar D, Jeggo PA and Lobrich M: An imperfect G2M checkpoint contributes to chromosome instability following irradiation of S and G2 phase cells. Cell Cycle 6: 1682-1686, 2007. (Pubitemid 47327917)
26. Bartek J and Lukas J: Mammalian G1-and S-phase checkpoints in response to DNA damage. Curr Opin Cell Biol 13: 738-747, 2001. (Pubitemid 33042735)
27. Taverna SD, Li H, Ruthenburg AJ, Allis CD and Patel DJ: How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat Struct Mol Biol 14: 1025-1040, 2007. (Pubitemid 350060344)
28. Mailand N, Falck J, Lukas C, et al: Rapid destruction of human Cdc25A in response to DNA damage. Science 288: 1425-1429, 2000. (Pubitemid 30366329)
29. Helt CE, Cliby WA, Keng PC, Bambara RA and O'Reilly MA: Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specifcities in response to different forms of DNA damage. J Biol Chem 280: 1186-1192, 2005.
30. Falck J, Mailand N, Syljuasen RG, Bartek J and Lukas J: The ATM-Chk2-Cdc25A checkpoint pathway guards against radio-resistant DNA synthesis. Nature 410: 842-847, 2001. (Pubitemid 32303786)
31. Kouzarides T: SnapShot: histone-modifying enzymes. Cell 131: 822, 2007.
32. Stucki M, Clapperton JA, Mohammad D, Yaffe MB, Smerdon SJ and Jackson SP: MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. Cell 123: 1213-1226, 2005. (Pubitemid 41821780)
33. Wu L, Luo K, Lou Z and Chen J: MDC1 regulates intra-S-phase checkpoint by targeting NBS1 to DNA double-strand breaks. Proc Natl Acad Sci USA 105: 11200-11205, 2008.